The Adverse Outcome Pathway (AOP) Pathways
This Adverse Outcome Pathway (AOP) Community is created to highlight the molecular basis of AOPs, or events in, AOPS. In general, AOPs start with a Molecular Initiating Event (MIE) caused by a stressor, followed by Key Events (KEs), that lead to an Adverse Outcome (AO). These AOPs are intended specifically for regulatory decision making and are typically stored in the AOP Knowledge Base (AOPKB). Because AOPs are simplified explanations of biological effects after the effect of a stressor they are not useful to describe and understand the molecular basis of the AOPs and not suited to do data analysis. Such analysis is needed especially for in silico risk analysis intending to lower animal use in toxicology studies. This community page was created to present this previously missing molecular level of the AOPs and get more into detail on the biological processes involved in them. The development of these molecular AOPS is relevant for the European research projects on toxicology EU-ToxRisk and OpenRiskNet that also funded part of the work. This community page is also featured in the latest NAR Database Issue on WikiPathways.
- COVID-19 adverse outcome pathway (Homo sapiens)
- Liver steatosis adverse outcome pathway (Homo sapiens)
- Lung fibrosis (Homo sapiens)
- Lung fibrosis (Mus musculus)
- Mitochondrial complex I inhibition leading to chemical-induced Fanconi syndrome (Homo sapiens)
- Nanomaterial induced apoptosis (Homo sapiens)
- Nanomaterial-induced inflammasome activation (Homo sapiens)
- Nanoparticle triggered autophagic cell death (Homo sapiens)
- Nanoparticle triggered regulated necrosis (Homo sapiens)
- Nanoparticle-mediated activation of receptor signaling (Homo sapiens)
- Overview of nanoparticle effects (Homo sapiens)
How to Contribute
The list of pathways is not static and can be updated at any time. If you know of a pathway that should be added, please contact the administrator, Marvin Martens (marvin.martens[AT]maastrichtuniversity.nl).
This project has received funding from the European Union’s Horizon 2020 research and innovation programme project EU-ToxRisk under grant agreement No. 681002 and EINFRA-22-2016 programme project OpenRiskNet under grant agreement No. 731075.
Authors of Community Pathways
Egonw, Anwesha, MaintBot, Bart Smeets, Fehrhart, Mkutmon, Torresandon, Wpblocked, DeSl, Khanspers, Marvin M2, Andra, Timverbruggen, Laurent, Elisa, Lindarieswijk, Eweitz, Penny, Jmelius, AlexanderPico, JJvdHeijden, Jkearns445, ChesdeWindt, Finterly, and Evelo.